心康冲剂对慢性心衰心肾阳虚证大鼠CD31、VEGF蛋白表达的作用研究
|
摘要
目的:探讨心康冲剂对心肾阳虚证心衰大鼠CD31、VEGF蛋白的作用研究。方法:70只SD大鼠随机分为假手术组10只,心阳虚组20只,心肾阳虚组20只,心肾阳虚组+心康冲剂组20只。实验结束后行血流动力学检测,采用ELISA法检血小板内皮细胞黏附分子1(CD31)、血管内皮生长因子(VEGF)水平,心脏切片行免疫荧光染色。结果:与假手术组比较,心肾阳虚组、心阳虚组、心康冲剂干预组大鼠LVAP、dp/dtmax、-dp/dtmax明显降低(P <0. 05),LVEDP、血浆CD31、VEGF水平明显升高(P﹤0. 05),免疫荧光染色显示CD31、VEGF荧光颗粒表达增多。与心肾阳虚组比较,心康冲剂干预组LVEDP、LVAP、dp/dtmax、-dp/dtmax明显增高(P <0. 05),CD31、VEGF水平明显降低(P <0. 05)。结论:心康冲剂可减少慢性心衰心肾阳虚证大鼠CD31、VEGF表达保护血管内皮。
Objective: To investigate the effect of Xinkang Granule( XKG) on protein of CD31 and VEGF in heart failure rats with heart-kidney Yang deficiency syndrome. Methods: 70 SD rats were randomly divided into sham operation group( n = 10),heart Yang deficiency group( n = 20),heart-kidney Yang deficiency group( n = 20),and XKG group( n = 20). After the experiment,hemodynamics test was performed. The levels of platelet endothelial cell adhesion molecule 1( CD31) and vascular endothelial growth factor( VEGF)were detected by ELISA. Immunofluorescence staining was performed on the heart slices. Results: Compared with the sham operation group,the rats of the heart-kidney Yang deficiency group,heart Yang deficiency group and XKG group showed LVEDP,LVAP,dp/dtmax,and-dp/dtmax decreased significantly( P < 0. 05),while the plasma level of CD31 and VEGF increased significantly( P < 0.05),the expression of CD31 and VEGF fluorescent particles increased. Compared with the heart-kidney Yang deficiency group,LVEDP,LVAP,dp/dtmax,and-dp/dtmax increased significantly in the XKG group( P < 0. 05),and the levels of CD31 and VEGF decreased significantly( P < 0. 05). XKG protect vascular endothelium by reducing the expression of CD31 and VEGF in rats of chronic heart failure and heart-yang deficiency syndrome.
Objective: To investigate the effect of Xinkang Granule( XKG) on protein of CD31 and VEGF in heart failure rats with heart-kidney Yang deficiency syndrome. Methods: 70 SD rats were randomly divided into sham operation group( n = 10),heart Yang deficiency group( n = 20),heart-kidney Yang deficiency group( n = 20),and XKG group( n = 20). After the experiment,hemodynamics test was performed. The levels of platelet endothelial cell adhesion molecule 1( CD31) and vascular endothelial growth factor( VEGF)were detected by ELISA. Immunofluorescence staining was performed on the heart slices. Results: Compared with the sham operation group,the rats of the heart-kidney Yang deficiency group,heart Yang deficiency group and XKG group showed LVEDP,LVAP,dp/dtmax,and-dp/dtmax decreased significantly( P < 0. 05),while the plasma level of CD31 and VEGF increased significantly( P < 0.05),the expression of CD31 and VEGF fluorescent particles increased. Compared with the heart-kidney Yang deficiency group,LVEDP,LVAP,dp/dtmax,and-dp/dtmax increased significantly in the XKG group( P < 0. 05),and the levels of CD31 and VEGF decreased significantly( P < 0. 05). XKG protect vascular endothelium by reducing the expression of CD31 and VEGF in rats of chronic heart failure and heart-yang deficiency syndrome.
引文
[1]孙莉,李树青.高血压致左室肥厚的发生机制及其治疗进展[J].中国心血管病研究杂志,2007,5(4):315-317.
[2]王玮,方志成,黄从新.心血管疾病与心肌微血管病变关系研究现状[J].心血管病学进展,2006,27(4):463-466.
[3] Gibbins JM. Platelet adhesion signaling and the regulation of thrombus formation[J]. J Cell Sci,2004,117(16):3 415-3 425.
[4]Heitzer T Baldus S von Kodolitsch Y eta1. Systemic endothelial dysfunction as an early predictor of adverse out comei n heart failure[J]. Arterioscler Thromb Vasc Biol,2005,25(2):1 174-1 179.
[5]De Berrazueta JR,Guerra-Ruiz A,Garcia-Unzueta MT,et a1. Endothelial dysfunction,measured by reactive hyperaemia using straingauge plethysmography,is an independent predictor of adverse outcome in heart failure[J]. Eur J Heart Failure,2010,5(1):477-483.
[6]吴时达,徐俊波,付远忠,等.慢性充血性心力衰竭心肾阳虚型大鼠模型的研究[J].中国中西医结合急救杂志,2002,9(4):197-201.
[7]成忠煌,胡雪峰.阿霉素诱导大鼠CHF模型给药剂量和频率的优化[J].湖北中医杂志,2011,33(4):9-11.
[8]XuK,George I,Klotz S,et a1. Erythropoietin derivate improvesleft ventricular systolic performance and attenuates left ventricularremodeling in rats with myocardial infarct-induced heart failure[J]. J Cardiovasc Pharmacol,2010,56(5):506-512.
[9]吴向东,邓继红.大鼠心肾阳虚证动物模型实验研究[J].基层中药杂志,2002,16(6):21-23.
[10]Meyer B,Mortl D,Strecker K,et a1. Flow-mediated vasodilation predicts outcome in patients with chronic heart failure,comparison with B-type natriuretic peptide[J]. J A m Coll Cardiol,2005,46(6):1 011-1 018.
[11]尹克春,吴焕林.邓铁涛教授调脾护心法治疗心力衰竭经验[J].新中医,2002,34(5):11-12.
[12]霍根红.充血性心力衰竭的中医病理实质[J].河南中医,2009,29(2):114-117.
[13]陈晶,匡海学.强心胶囊对阿霉素诱导大鼠心衰模型神经内分泌功能的影响[J].中医药学报,2009,37(5):38-41.
[14]赵金龙,李大锋,管益国,等.慢性心力衰竭患者左室射血分数与中医证型关系的研究[J].现代中西医结合杂志,2011(31):3912-3 913,3 916.
[15]Collins RG,Velji R,Guevara NV,et a1. P-Selectin or intercellular adhesion molecule(ICAM)-1 deficiency substantially protects against atherosclemsis in apolipoprotein E-deficient mice[J]. The Journal of experimental medicine,2000,191(4):189-194.
[16]Chong AY,Blann AD,Patel J,et a1. Endothelial dysfunction and damage in Congestive heart failure:relation of flow-mediated dilation to circulating endothelial cells,plasma indexes of endothelial damage,and brain natriuretic peptide[J]. Circulation,2004,110(4):1 794-1 798.
[17]Besnier M,Galaup A,Nicol L,et al. Enhanced angiogenesis and increased cardiac perfusion after myocardial infarction in protein tyrosine phosphatase 1B-deficient mice[J]. FASEB journal:official publication of the Federation of American Societies for Experimental Biology,2014,28(8):3 351-3 361.
[18]Pearson TA,Mensah GA,Alexander RW,et al. Markers of inflammation and cardiovascular disease,application to clinical and public health practice:a statement for healthcare professionals from the centers for disease control and prevention and the American Heart Association[J]. Circulation,2003,107(3):499-512.
[2]王玮,方志成,黄从新.心血管疾病与心肌微血管病变关系研究现状[J].心血管病学进展,2006,27(4):463-466.
[3] Gibbins JM. Platelet adhesion signaling and the regulation of thrombus formation[J]. J Cell Sci,2004,117(16):3 415-3 425.
[4]Heitzer T Baldus S von Kodolitsch Y eta1. Systemic endothelial dysfunction as an early predictor of adverse out comei n heart failure[J]. Arterioscler Thromb Vasc Biol,2005,25(2):1 174-1 179.
[5]De Berrazueta JR,Guerra-Ruiz A,Garcia-Unzueta MT,et a1. Endothelial dysfunction,measured by reactive hyperaemia using straingauge plethysmography,is an independent predictor of adverse outcome in heart failure[J]. Eur J Heart Failure,2010,5(1):477-483.
[6]吴时达,徐俊波,付远忠,等.慢性充血性心力衰竭心肾阳虚型大鼠模型的研究[J].中国中西医结合急救杂志,2002,9(4):197-201.
[7]成忠煌,胡雪峰.阿霉素诱导大鼠CHF模型给药剂量和频率的优化[J].湖北中医杂志,2011,33(4):9-11.
[8]XuK,George I,Klotz S,et a1. Erythropoietin derivate improvesleft ventricular systolic performance and attenuates left ventricularremodeling in rats with myocardial infarct-induced heart failure[J]. J Cardiovasc Pharmacol,2010,56(5):506-512.
[9]吴向东,邓继红.大鼠心肾阳虚证动物模型实验研究[J].基层中药杂志,2002,16(6):21-23.
[10]Meyer B,Mortl D,Strecker K,et a1. Flow-mediated vasodilation predicts outcome in patients with chronic heart failure,comparison with B-type natriuretic peptide[J]. J A m Coll Cardiol,2005,46(6):1 011-1 018.
[11]尹克春,吴焕林.邓铁涛教授调脾护心法治疗心力衰竭经验[J].新中医,2002,34(5):11-12.
[12]霍根红.充血性心力衰竭的中医病理实质[J].河南中医,2009,29(2):114-117.
[13]陈晶,匡海学.强心胶囊对阿霉素诱导大鼠心衰模型神经内分泌功能的影响[J].中医药学报,2009,37(5):38-41.
[14]赵金龙,李大锋,管益国,等.慢性心力衰竭患者左室射血分数与中医证型关系的研究[J].现代中西医结合杂志,2011(31):3912-3 913,3 916.
[15]Collins RG,Velji R,Guevara NV,et a1. P-Selectin or intercellular adhesion molecule(ICAM)-1 deficiency substantially protects against atherosclemsis in apolipoprotein E-deficient mice[J]. The Journal of experimental medicine,2000,191(4):189-194.
[16]Chong AY,Blann AD,Patel J,et a1. Endothelial dysfunction and damage in Congestive heart failure:relation of flow-mediated dilation to circulating endothelial cells,plasma indexes of endothelial damage,and brain natriuretic peptide[J]. Circulation,2004,110(4):1 794-1 798.
[17]Besnier M,Galaup A,Nicol L,et al. Enhanced angiogenesis and increased cardiac perfusion after myocardial infarction in protein tyrosine phosphatase 1B-deficient mice[J]. FASEB journal:official publication of the Federation of American Societies for Experimental Biology,2014,28(8):3 351-3 361.
[18]Pearson TA,Mensah GA,Alexander RW,et al. Markers of inflammation and cardiovascular disease,application to clinical and public health practice:a statement for healthcare professionals from the centers for disease control and prevention and the American Heart Association[J]. Circulation,2003,107(3):499-512.